KEGG   DRUG: Imiglucerase
Entry
D03020                      Drug                                   
Name
Imiglucerase (USAN/INN);
Imiglucerase (genetical recombination) (JAN);
Cerezyme (TN)
Product
CEREZYME (Genzyme Corporation)
Formula
C2532H3843N671O711S16
Exact mass
55537.0717
Mol weight
55571.74
Sequence
ARPCIPKSFG YSSVVCVCNA TYCDSFDPPT FPALGTFSRY ESTRSGRRME LSMGPIQANH
TGTGLLLTLQ PEQKFQKVKG FGGAMTDAAA LNILALSPPA QNLLLKSYFS EEGIGYNIIR
VPMASCDFSI RTYTYADTPD DFQLHNFSLP EEDTKLKIPL IHRALQLAQR PVSLLASPWT
SPTWLKTNGA VNGKGSLKGQ PGDIYHQTWA RYFVKFLDAY AEHKLQFWAV TAENEPSAGL
LSGYPFQCLG FTPEHQRDFI ARDLGPTLAN STHHNVRLLM LDDQRLLLPH WAKVVLTDPE
AAKYVHGIAV HWYLDFLAPA KATLGETHRL FPNTMLFASE ACVGSKFWEQ SVRLGSWDRG
MQYSHSIITN LLYHVVGWTD WNLALNPEGG PNWVRNFVDS PIIVDITKDT FYKQPMFYHL
GHFSKFIPEG SQRVGLVASQ KNDLDAVALM HPDGSAVVVV LNRSSKDVPL TIKDPAVGFL
ETISPGYSIH TYLWHRQ
  Type
Peptide
Remark
Therapeutic category: 3959
ATC code: A16AB02
Product: D03020<JP/US>
Efficacy
Lysosomal storage disease treatment, Enzyme replacement (glucocerebrosidase)
  Disease
Gaucher disease [DS:H00126]
  Type
Enzyme replacement therapy product
Target
GBA* [HSA_VAR:2629v1] [HSA:2629] [KO:K01201]
  Pathway
hsa00511  Other glycan degradation
hsa00600  Sphingolipid metabolism
hsa04142  Lysosome
  Network
nt06014  Sphingolipid degradation
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AB Enzymes
     A16AB02 Imiglucerase
      D03020  Imiglucerase (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Imiglucerase
   D03020  Imiglucerase (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D03020  Imiglucerase (USAN/INN); Imiglucerase (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Glycosidases
    GBA* [HSA_VAR:2629v1]
     D03020  Imiglucerase (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03020
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D03020
Other DBs
CAS: 154248-97-2
PubChem: 47205823
LinkDB

» Japanese version   » Back

KEGG   DRUG: Velaglucerase alfa
Entry
D09029                      Drug                                   
Name
Velaglucerase alfa (USAN);
Velaglucerase alfa (genetical recombination) (JAN);
Vpriv (TN)
Product
VPRIV (Takeda Pharmaceuticals America)
Formula
C2532H3854N672O711S16
Exact mass
55562.1608
Mol weight
55596.83
Sequence
ARPCIPKSFG YSSVVCVCNA TYCDSFDPPT FPALGTFSRY ESTRSGRRME LSMGPIQANH
TGTGLLLTLQ PEQKFQKVKG FGGAMTDAAA LNILALSPPA QNLLLKSYFS EEGIGYNIIR
VPMASCDFSI RTYTYADTPD DFQLHNFSLP EEDTKLKIPL IHRALQLAQR PVSLLASPWT
SPTWLKTNGA VNGKGSLKGQ PGDIYHQTWA RYFVKFLDAY AEHKLQFWAV TAENEPSAGL
LSGYPFQCLG FTPEHQRDFI ARDLGPTLAN STHHNVRLLM LDDQRLLLPH WAKVVLTDPE
AAKYVHGIAV HWYLDFLAPA KATLGETHRL FPNTMLFASE ACVGSKFWEQ SVRLGSWDRG
MQYSHSIITN LLYHVVGWTD WNLALNPEGG PNWVRNFVDS PIIVDITKDT FYKQPMFYHL
GHFSKFIPEG SQRVGLVASQ KNDLDAVALM HPDGSAVVVV LNRSSKDVPL TIKDPAVGFL
ETISPGYSIH TYLWRRQ (Glycosylation site: 19; 59; 146; 270; 462)
  Type
Peptide
Remark
Therapeutic category: 3959
ATC code: A16AB10
Product: D09029<JP/US>
Efficacy
Lysosomal storage disease treatment, Enzyme replacement (glucocerebrosidase)
  Disease
Type 1 Gaucher disease [DS:H00126]
  Type
Enzyme replacement therapy product
Target
GBA* [HSA_VAR:2629v1] [HSA:2629] [KO:K01201]
  Pathway
hsa00511  Other glycan degradation
hsa00600  Sphingolipid metabolism
hsa04142  Lysosome
  Network
nt06014  Sphingolipid degradation
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AB Enzymes
     A16AB10 Velaglucerase alfa
      D09029  Velaglucerase alfa (USAN) <JP/US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Velaglucerase Alfa
   D09029  Velaglucerase alfa (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D09029  Velaglucerase alfa (USAN); Velaglucerase alfa (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Glycosidases
    GBA* [HSA_VAR:2629v1]
     D09029  Velaglucerase alfa (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09029
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09029
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09029
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09029
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D09029
Other DBs
CAS: 884604-91-5
PubChem: 96025712
LinkDB

» Japanese version   » Back

KEGG   DRUG: Taliglucerase alfa
Entry
D09675                      Drug                                   
Name
Taliglucerase alfa (USAN/INN);
Alfataliglucerase;
Elelyso (TN);
Uplyso (TN)
Product
ELELYSO (Pfizer Laboratories Div Pfizer)
Formula
C2580H3918N680O727S17
Exact mass
56602.5769
Mol weight
56637.97
Sequence
EFARPCIPKS FGYSSVVCVC NATYCDSFDP PTFPALGTFS RYESTRSGRR MELSMGPIQA
NHTGTGLLLT LQPEQKFQKV KGFGGAMTDA AALNILALSP PAQNLLLKSY FSEEGIGYNI
IRVPMASCDF SIRTYTYADT PDDFQLHNFS LPEEDTKLKI PLIHRALQLA QRPVSLLASP
WTSPTWLKTN GAVNGKGSLK GQPGDIYHQT WARYFVKFLD AYAEHKLQFW AVTAENEPSA
GLLSGYPFQC LGFTPEHQRD FIARDLGPTL ANSTHHNVRL LMLDDQRLLL PHWAKVVLTD
PEAAKYVHGI AVHWYLDFLA PAKATLGETH RLFPNTMLFA SEACVGSKFW EQSVRLGSWD
RGMQYSHSII TNLLYHVVGW TDWNLALNPE GGPNWVRNFV DSPIIVDITK DTFYKQPMFY
HLGHFSKFIP EGSQRVGLVA SQKNDLDAVA LMHPDGSAVV VVLNRSSKDV PLTIKDPAVG
FLETISPGYS IHTYLWHRQD LLVDTM
(Disulfide bridge: 6-18, 20-25)
  Type
Peptide
Remark
ATC code: A16AB11
Product: D09675<US>
Efficacy
Lysosomal storage disease treatment, Enzyme replacement (glucocerebrosidase)
  Disease
Type 1 Gaucher disease [DS:H00126]
  Type
Enzyme replacement therapy product
Target
GBA* [HSA_VAR:2629v1] [HSA:2629] [KO:K01201]
  Pathway
hsa00511  Other glycan degradation
hsa00600  Sphingolipid metabolism
hsa04142  Lysosome
  Network
nt06014  Sphingolipid degradation
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AB Enzymes
     A16AB11 Taliglucerase alfa
      D09675  Taliglucerase alfa (USAN/INN) <US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Taliglucerase Alfa
   D09675  Taliglucerase alfa (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Glycosidases
    GBA* [HSA_VAR:2629v1]
     D09675  Taliglucerase alfa (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09675
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09675
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D09675
Other DBs
CAS: 37228-64-1
PubChem: 124490415
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system